NewsRoom Articles - Page 97 of 154 - PsychedelicNewsWire (PNW)

ThursdayMay 27, 2021 12:30 pm

Legendary Investor Believes Investment Potential of Psychedelics Exceeds That of Marijuana

Psychedelics drugs are becoming more popular as more research discovers the potential they possess for treating various mental health conditions. These substances have been ignored since the 1960s, and while they are still illegal in various states across the country, many companies are betting that the substances will be big, given both the anecdotal and preliminary scientific evidence showing that the compounds may be even more efficacious than the current pharmaceuticals prescribed to manage various disorders. These findings have garnered the attention of many, from Wall Street to independent investors, who believe that psychedelics will be huge in the near…

WednesdayMay 26, 2021 2:30 pm

Psychedelic Expert Thinks Legalizing Psychedelic Medicine May Put End to Persecution, Incarceration of Minorities

For many centuries now, psychedelics have been used by various communities and groups. Many doubt that there’s a human society in recorded history that hasn’t used psychedelics to experiment with altered states of consciousness. It is well known that psychedelics have been used by various indigenous groups of the Americas and are regarded as sacred plants. The plants have been used to explain the myths regarding the existence of humans on earth, teach younger generations, develop socializations and guide cultures. However, the use of psychedelics isn’t exclusive to indigenous groups, as records show that ancient Greeks also used the natural…

WednesdayMay 26, 2021 9:00 am

Cybin Inc. (NEO: CYBN) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio

Company files 12th patent to strengthen proprietary IP program Cybin believes treatments can decrease costs, increase access to important therapeutics Patent provides wide range of benefits in Cybin’s four drug candidate program Cybin (NEO: CYBN) (OTCQB: CLXPF) has filed a new provisional patent application designed to strengthen the company’s ongoing drug candidate programs (https://ibn.fm/9V5sv). Cybin, a biotechnology company focused on progressing psychedelic therapeutics, is focused on expanding its four active drug programs targeting depression, addiction and other psychiatric conditions alongside its growing portfolio of 50+ proprietary psychedelic molecules. “By continuing to innovate in directions to enhance the patient experience and…

TuesdayMay 25, 2021 2:15 pm

Wesana Health, WBC Partner to Study Psychedelics as Treatment for TBIs

Daniel Carcillo retired from the National Hockey League in 2015, after nine seasons in the game. He had been diagnosed with several concussions and had struggled with insomnia, depression, anxiety, headaches and even slurred speech in his professional seasons as a hockey player. Determined to get better, Carcillo implemented lifestyle changes that included the use of psilocybin, an active ingredient found in magic mushrooms, as well as eating healthier and getting more sleep. This, he said, helped improve his overall heath tremendously. He is now dedicating his life to helping other individuals like himself as well as athletes who have…

MondayMay 24, 2021 3:00 pm

FDA Grants Authorization Allowing Research Institute to Study Psychedelic Use by Therapists

The Multidisciplinary Association for Psychedelic Studies (“MAPS”) was recently granted authorization to administer MDMA to therapists. This comes after the FDA, which gave its approval, also allowed institutes to conduct clinical trials on MDMA and its therapeutic potential in treating PTSD. The therapists, who have all volunteered, are currently undergoing training on how to treat individuals suffering from post-traumatic stress disorder and will be allowed to take part in phase 1 trials in an attempt to acquire personal experience from this treatment option. This complementary research project will be conducted by MAPS, which is also conducting phase 3 clinical trials…

MondayMay 24, 2021 1:51 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts

Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needs The company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disorders Tryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering drugs to treat select neurological conditions when paired with the care of a trained therapist The company has been preparing to initiate a Phase 2a clinical trial for the psychedelic candidate in partnership with a medical research team at the University of Florida The idea…

FridayMay 21, 2021 2:00 pm

Core One Labs Begins Development of Psychedelic-Based Treatment for Alzheimer’s

Core One Labs Inc., a biotech and life sciences company, recently announced that its wholly owned subsidiary, Akome Biotech Ltd, has started to develop a psychedelic drug formulation indicated for Alzheimer’s treatment. The formulation, which has been dubbed ALO002, is made up of a plant bioactive and psilocybin, which is the active compound found in magic mushrooms. Researchers believe that the two ingredients are synergistic in treating the neurological disorder. The company recently filed a provisional patent application for the candidate with the United States Patent and Trademark Office. Alzheimer’s is a progressive neurologic disease that is irreversible and destroys…

ThursdayMay 20, 2021 2:00 pm

First Psychedelics Training Program Targeting Canadian Mental Health Workers Ends Successfully

ATMA Inc. has partnered with Wayfound and the PAA (a professional body bringing together all psychology professionals within Alberta province in Canada) to conduct the first-ever training program aimed at equipping licensed mental health professionals with the skills that they need to include psychedelic-assisted psychotherapy on the list of services available to patients. The training program was announced for the first time in February, and available slots quickly filled, leaving other interested professionals to join a long waitlist for the next phase of this training. This huge interest in the course underscores how much the mental health community would like…

WednesdayMay 19, 2021 3:30 pm

Psychedelics Researchers Target Systemic Inflammation

While medical science is still working to establish how different cannabinoids can best be used to combat widespread/systemic inflammation, psychedelics researchers are hard at work to develop a “wonder drug” for systemic inflammation from psychedelics. An LSU Health Sciences Center team is looking into how DOI, a synthetic psychedelic substance that is similar to LSD, can be refined in order to exploit its anti-inflammatory effects. Eleusis, a life sciences company, is working with the LSU researchers. Charles Nichols is a pharmacology professor and also the scientific founder at Eleusis. He has proven that DOI is good at not only preventing…

TuesdayMay 18, 2021 2:00 pm

Harvard Scientist Sets Out to Create Psychedelic Drugs Analogues

Jonathan Sporn, a former scientist at NIH and Harvard, has announced that his new company, Gilgamesh Pharmaceuticals, has raised a total of $27 million in its Series A funding round. The firm intends to use the money collected to prepare four drug candidates for Investigational New Drug (“IND”) applications to the FDA. This isn’t the first time that Sporn is venturing into the psychedelics sector. His first foray, through Perception Neuroscience, saw his team focus all their attention on developing a mental health drug from R-ketamine to treat depression that is unresponsive to existing medications. At the beginning of 2019,…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000